FORMULATION AND EVALUATION OF EXTENDED RELEASE OSELTAMIVIR CAPSULES 75 MG

Abstract

The current research work predicts the applicability of QbD in manufacturing Oseltamivir Capsules 75 mg ER Capsules by using rate delaying polymers. From the outcomes it was clearly apparent that as the polymer concentration increases, there was a decline in the release of drug. Grouping of polymers with other excipients do not interact with drug and vice versa, which information to sustained delivery of drug for longer periods. The enhanced formulation from factorial design can be used as a single dose per day in the organization of HIV/AIDS.Wet granulation procedure was the chosen technology for the preparation of Oseltamivir phosphate capsule. Based on the preliminary studies, different formulation trials (F1-F7) were carried out with different concentrations of disintegrants, diluents. From the various formulations it was decided that the formulation batch of F7 was finalized as the optimized formula. Formulation F7 showed satisfactory results with various physicochemical evaluation parameters like Disintegration time, Dissolution profile, Assay when matched with that of the marketed product. The stability studies at all condition, indicates that the formulated capsules were found to be stable. Hence, it is finally concluded that, Oseltamivir phosphate capsules are pharmaceutically comparable, low cost, quality improved and stable formulation.